Àº¿À°å³Ø¤Î³¤Ï·¤Ç¤ó¤¹

¤¢¤¿¤ê¤Þ¤¨¤Ë²Ê³ØÅª¤Ê°åÎŤò¤·¤¿¤¤¤±¤É¡ÊÃæ¿È¤Î¤Ê¤¤½ñ¸Ë¤¬Áý¤¨¤Þ¤·¤¿¡Ë

F0¡ÊÃÔÊò¡¦´ï¼Á¡¦¾É¾õÀ­¡Ë

[ ¥ê¥¹¥È | ¾ÜºÙ ]

µ­»ö¸¡º÷
¸¡º÷

Á´1¥Ú¡¼¥¸

[1]

½¾Íè·¿¤ÈPEG¡¤¥¤¥ó¥¿¡¼¥Õ¥§¥í¥ó¤ÎÀº¿À¾É¾õ¤ÎÈæ³Ó

ɽÂê¡§PEG¥¤¥ó¥¿¡¼¥Õ¥§¥í¥ó¤È½¾Íè¤Î¥¤¥ó¥¿¡¼¥Õ¥§¥í¥ó¤ÎÀº¿À¾É¾õ¤ÎÉûºîÍѤÎÈæ³Ó
ÌÜŪ¡§Î¾¼Ô¤Î¡¢¤¦¤Ä¾õÂ֤ؤαƶÁ¤òɾ²Á
ÊýË¡¡§C·¿´Î±ê98Îã¤Ë¤Ä¤¤¤Æ¡¢½¾Íè¤Î¦Á2b¡§48Îã¡¢PEG¦Á2b¡Ü¥ê¥Ð¥Ó¥ê¥ó¡§50Îã¤Ç¶èʬ¡¢HADS¤Ê¤é¤Ó¤ËSCL-90-R¤ò³«»ÏÁ°¡¢³«»Ï¸å3²ó¬Äê¡£
·ë²Ì¡§¤¦¤Ä¾õÂÖ¤ÎÄøÅÙ¤Ïξ·²¤È¤âÎà»÷¡ÊANOVA: P = 0.875¡Ë¤·¡¢Î×¾²Åª¤Ë´ØÏ¢¤¬¤¢¤ê¤½¤¦¤ÊÍÞ¤¦¤Ä¼ÜÅÙ¤¬¤â¤Ã¤È¤â¹â¤¤´µ¼Ô¤ÏPEG·²¤Ç¤¢¤Ã¤¿¡£Åܤꡢ¹¶·âÀ­¤Ë¤Ïº¹°Û¤Ï¤Ê¤«¤Ã¤¿¡£
¤Þ¤È¤á¡§Àº¿À¾É¾õ¤Ï¡¢¤É¤Á¤é¤Î¥¤¥ó¥¿¡¼¥Õ¥§¥í¥ó¤â¡¢ÊѤï¤é¤Ê¤«¤Ã¤¿¡£
Êó¹ðÃÏ¡§Wurzburg, Germany
½Ðŵ¡§Kraus MR, Schafer A, Csef H, Scheurlen M. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol. 2005 Mar 28;11(12):1769-74.
PMID: 15793861

ÆÉ¤ó¤ÀÉôʬ¡ÊÁ´Ê¸¤«Í×Ìó¤Î¤ß¤«¡Ë¡§Í×Ìó¤Î¤ß
ÆÉ¤ó¤ÀÍýͳ¡§¥¤¥ó¥¿¡¼¥Õ¥§¥í¥óÎÅË¡Ãæ¡¢Àº¿À¾É¾õ¤¬½Ð¤Æ¡¢Â³¤±¤ë¤«¡¢¤ä¤á¤¿Êý¤¬¤¤¤¤¤«¤É¤¦¤«¡¢¶áÎÙ¤ÎÆâ²Ê°å»Õ¤«¤éÁêÃ̤ò¼õ¤±¤¿¡£
´¶ÁÛ¡§PEG¥¤¥ó¥¿¡¼¥Õ¥§¥í¥ó¤Ï¡¢½µ£±²óÅêÍ¿¡¢¥ê¥Ð¥Ó¥ê¥óÊ»ÍѤÀ¤ÈÉûºîÍѤ¬¾¯¤Ê¤¤¤È¤¤¤¦¤Õ¤ì¤³¤ß¤Ç¤¢¤Ã¤¿¤¬¡¢¤½¤¦¤Ç¤â¤Ê¤µ¤½¤¦¡£
¤½¤Î¾¡§·Úí¯¾õÂÖ¤ä¡¢í¯¤¦¤Äº®¹ç¾õÂÖ¤À¤È¡¢¤É¤¦¤·¤è¤¦...¡£




¡¡Àº¿À¾É¾õ¤Ë¤è¤ë¥¤¥ó¥¿¡¼¥Õ¥§¥í¥óÎÅË¡¤ÎÃæ»ß´ð½à

ɽÂê¡§ËýÀ­´Î±ê¤ËÂФ¹¤ë¥¤¥ó¥¿¡¼¥Õ¥§¥í¥ó¼£ÎŤËȼ¤¦Àº¿À¾É¾õ¡ÊÁíÀâ¡Ë
¼ç¤ÊÆâÍÆ¡§¼¡¤Î¤¤¤º¤ì¤«¤¬¤¢¤ì¤Ð¡¢¥¤¥ó¥¿¡¼¥Õ¥§¥í¥óÎÅË¡¤ÏÃæ»ß¤ò´«¤á¤ë¤³¤È¡£

¼«»¦´ë¿Þ¤Þ¤¿¤ÏÃæÅùÅٰʾå¤Î¼«»¦Ç°Î¸
¹³¤¦¤ÄºÞ¤ÎÁÕ¸ù¤·¤Ê¤¤¤¦¤Ä¾õÂÖ
í¯¾õÂÖ
¸¸³ÐÌÑÁÛ¾õÂÖ
¤»¤óÌѾõÂÖ

ÆÉ¤ó¤ÀÉôʬ¡ÊÁ´Ê¸¤«Í×Ìó¤Î¤ß¤«¡Ë¡§Á´Ê¸¤Ê¤Ê¤á¤è¤ß
ÆÉ¤ó¤ÀÍýͳ¡§¥¤¥ó¥¿¡¼¥Õ¥§¥í¥óÎÅË¡Ãæ¡¢Àº¿À¾É¾õ¤¬½Ð¤Æ¡¢Â³¤±¤ë¤«¡¢¤ä¤á¤¿Êý¤¬¤¤¤¤¤«¤É¤¦¤«¡¢¶áÎÙ¤ÎÆâ²Ê°å»Õ¤«¤éÁêÃ̤ò¼õ¤±¤¿¡£
´¶ÁÛ¡§¤³¤ÎÁíÀâ¤Ï¡¢¥¤¥ó¥¿¡¼¥Õ¥§¥í¥óÎÅË¡Ãæ¤Ë½Ð¸½¤·¤¿Àº¿À¾É¾õ¤ËÂФ·¤Æ¡¢Â¿¤¯¤ÎÊó¹ðÎã¤òÀººº¤·¡¢¤É¤Î¤è¤¦¤Êžµ¢¤Ë¤Ê¤Ã¤¿¤«¤ò¤Þ¤È¤á¡¢Ãæ»ß¤Î´ð½à¤È¤·¤Æ¹Í¤¨¤é¤ì¤ë¤â¤Î¤òÄ󼨤·¤Æ¤¤¤ë¡£¤¹¤Ã¤­¤ê¤Þ¤È¤á¤Æ¤¢¤ê¡¢ÉÔÊÙ¶¯¤À¤Ã¤¿¤¬¡¢ÂçÊÑ»²¹Í¤Ë¤Ê¤Ã¤¿¡£
¡¡¤¿¤À¡¢¾åµ­¾É¾õ¤¬¤¢¤Ã¤Æ¤â¡¢Ëܿͤ¬¼£Îŷѳ¤ò´õ˾¤¹¤ë¤³¤È¤â¤¢¤ë¡£Àº¿À²Ê°å»Õ¤È¤·¤Æ¤â¡¢¼£ÎŤò¤ä¤á¤è¤È¤¤¤¦¤Î¤Ï¡¢¤«¤«¤Ã¤¿»þ´Ö¤È¤ª¶â¡¢Ï«ÎϤΤ¹¤Ù¤Æ¤ò¤¢¤­¤é¤á¡¢´Î±ê¤ÎºÆÈ¯¤ò¼õ¤±Æþ¤ì¤è¡¢¤È¤¤¤¦¤Î¤ËÅù¤·¤¯¡¢¤Ä¤é¤¤¤È¤³¤í¡£¤·¤«¤·¡¢¼£ÎŤòÃæ»ß¤»¤º¤Ë·Ñ³¤·¤¿¾ì¹ç¡¢¤É¤Î¤¯¤é¤¤Àº¿À¾É¾õ¤Ë¤è¤ë»àË´¡¢Ä¹´üÎÅÍܤʤɡ¢½ÅÂç¤ÊÌäÂ꤬µ¯¤³¤ë¤«¤Ë¤Ä¤¤¤Æ¤Ï¡¢¸ÀµÚ¤µ¤ì¤Æ¤¤¤Ê¤¤¡£
¡¡¥¤¥ó¥¿¡¼¥Õ¥§¥í¥óÎÅË¡¤ÏÈñÍѤ⤫¤«¤ê¡¢¿ÈÂÎŪ¡¢Àº¿ÀŪ¤ÊÉéô¤âÂ礭¤Ê¤â¤Î¤Ç¤¢¤ë¤«¤é¤Ë¤Ï¡¢À®¸ù¤µ¤»¤¿¤¤¤È¤³¤í¤Ç¡¢¤É¤ÎÄøÅÙ¤Î´í¸±¤¬¶ñÂÎŪ¤Ë¤¢¤ë¤Î¤«¡¢¤ï¤«¤Ã¤Æ¤¤¤ì¤Ð¡¢Ãæ»ß¤È¡¢¤¢¤ë¤¤¤Ï¤É¤³¤Þ¤Ç¤Ï¤¬¤ó¤Ð¤ì¤ë¤Î¤«¤¬¡¢¤ï¤«¤ë¤«¤â¤È¤â»×¤¦¡£¤½¤Î¤¢¤¿¤ê¤ÎÅö»ö¼Ô¤ä°å»Õ¤ÎǺ¤ß¤Ï¡¢Ãø¼Ô¤Ï½½Ê¬¤ï¤«¤Ã¤Æ¤¤¤ë¤Î¤À¤í¤¦¤¬¡¢¤¤¤Þ¤¤¤Á¡¢¤«¤æ¤¤¤È¤³¤í¤Ë¼ê¤¬ÆÏ¤¤¤Æ¤¤¤Ê¤¤´¶¤¸¤â¤¢¤ë¡£
¡¡º£Æü¡¢Ãø¼Ô¤ÎÅØÎϤ˵ߤï¤ì¤¿¤Î¤Ç¡¢¤½¤ÎÅÀ¤ÏÁÇľ¤Ë´¶¼Õ¤·¤Ä¤Ä¡¢¤³¤ó¤Êµ¿Ì䤬»Ä¤Ã¤¿¡£º£¸å¤Î¸¦µæ¤Ë´üÂÔ¤·¤¿¤¤¡£
¤½¤Î¾¡§·Úí¯¾õÂÖ¤ä¡¢í¯¤¦¤Äº®¹ç¾õÂÖ¤À¤È¡¢¤É¤¦¤¹¤ë¤«¡¢¤É¤Î¤¯¤é¤¤¤Î´í¸±¤¬¤¢¤ë¤«¡¢¤È¤¤¤Ã¤¿¤³¤È¤¬ÌäÂê¤Ë¤Ê¤ê¤½¤¦¡£

½Ðŵ¡§ºÙÅÄâûÊ,²ÏÌîÄÌÀ¹,·§ÅÄÇî¸÷,ËýÀ­´Î±ê¤ËÂФ¹¤ë¥¤¥ó¥¿¡¼¥Õ¥§¥í¥ó¼£ÎŤËȼ¤¦Àº¿À¾É¾õ,Àº¿À¿À·Ð»ï105(6)768-786¡¤2003
Hosoda S, Kohno M, Kumada H. [Psychiatric symptoms related to interferon treatment for chronic hepatitis][Article in Japanese] Seishin Shinkeigaku Zasshi. 2003;105(6):768-86.
¥ê¥ó¥¯Àè¡ÊPMID¤Ê¤É¡Ë¡§14560593



Á´1¥Ú¡¼¥¸

[1]


.
evi*enc*_*f_p*ychia*ry
evi*enc*_*f_p*ychia*ry
ÃËÀ­ / Èó¸ø³«
¿Íµ¤ÅÙ
Yahoo!¥Ö¥í¥°¥Ø¥ë¥× - ¥Ö¥í¥°¿Íµ¤Å٤ˤĤ¤¤Æ

²áµî¤Îµ­»ö°ìÍ÷

¸¡º÷ ¸¡º÷
Æü ·î ²Ð ¿å ÌÚ ¶â ÅÚ
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

¤è¤·¤â¤È¥Ö¥í¥°¥é¥ó¥­¥ó¥°

¤â¤Ã¤È¸«¤ë

[PR]¤ªÆÀ¾ðÊó

¤Õ¤ë¤µ¤ÈǼÀÇ¥µ¥¤¥È¡Ø¤µ¤È¤Õ¤ë¡Ù
¼Â¼Á2000±ß¤ÇÆÃ»ºÉʤ¬¤ª¼ê¸µ¤Ë
11¡¿30¤Þ¤Ç¥­¥ã¥ó¥Ú¡¼¥ó¼Â»ÜÃæ¡ª

¤½¤Î¾¤Î¥­¥ã¥ó¥Ú¡¼¥ó


¤ß¤ó¤Ê¤Î¹¹¿·µ­»ö